Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment.

Molecular cancer research : MCR - 1 Sept 2009

Bougherara Houcine, Subra Frédéric, Crépin Ronan, Tauc Patrick, Auclair Christian, Poul Marie-Alix

Abstract excerpt

Kit is a cell surface type III tyrosine kinase (TK) receptor implicated in cell transformation through overexpression or oncogenic mutation. Two categories of Kit mutants displaying mutations either in the juxtamembrane intracellular domain (regulatory mutants) or in the catalytic domain (catalytic mutants) have been described. To explore the effect of Kit oncogenic mutations on its subcellular localization, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Cricetulus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dasatinib

Share to Imatinib Mesylate

Share to Intracellular Space

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Thiazoles

Source

Identifiers

PMID: 19737976
DOI: 10.1158/1541-7786.MCR-09-0138

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment.PMID 19737976Read ↗

Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.Semantic proximity Read ↗

Golgi Retention and Oncogenic Signaling of KIT Tyrosine Kinase in Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

KIT D816V is dimerization-independent and activates downstream pathways frequently perturbed in mastocytosis.Semantic proximity Read ↗

Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition.Semantic proximity Read ↗

Normal and oncogenic forms of the receptor tyrosine kinase kit.Semantic proximity Read ↗

KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors.Semantic proximity Read ↗

The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.Semantic proximity Read ↗

Gene expression patterns of hemizygous and heterozygous KIT mutations suggest distinct oncogenic pathways: a study in NIH3T3 cell lines and GIST samples.Semantic proximity Read ↗

The tyrosine kinase FES is an essential effector of KITD816V proliferation signal.Semantic proximity Read ↗

The strength and cooperativity of KIT ectodomain contacts determine normal ligand-dependent stimulation or oncogenic activation in cancer.Semantic proximity Read ↗

Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.Semantic proximity Read ↗

Role of intracellular tyrosines in activating KIT-induced myeloproliferative disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.